Power Of Rare Disease Patient Registries Touted By US FDA, Patients
Executive Summary
Patients describe how they connect with each other and advance research through registries; agency says it has accepted registry data as real-world evidence of a product's benefit.
You may also be interested in...
What Would US FDA Do If Supreme Court Eliminates Or Curtails Chevron Deference?
Lawyers say agency will have to bolster its administrative record as judges tackle complex policy and scientific issues previously left to FDA. Some cases, such as challenges to exclusivity decisions, may be reopened.
What Will FDA Do If Supreme Court Curtails Chevron Deference?
Lawyers say agency will have to bolster its administrative record as judges tackle complex policy and scientific issues previously left to FDA. Some cases, such as challenges to exclusivity decisions, may be reopened.
FTC Expands PBM Probe To Group Purchasing Organizations
Commission issues compulsory orders for information to two organizations that negotiate drug rebates on behalf of CVS Caremark, Express Scripts and other PBMs. It issued similar orders to the six largest PBMs last year.